Niven Narain, PhD profile page

Dr. Niven Narain is the Chairman, President, and CEO of BPGbio, where his visionary leadership and innovative approach have revolutionized drug discovery and development. Under his guidance, BPGbio has pioneered the NAi Interrogative Biology® Platform, the first biology-first AI drug discovery platform. This cutting-edge platform integrates a proprietary biobank with the world’s fastest supercomputer at Oak Ridge National Laboratory, enabling AI-driven target nomination, discovery, molecule design, and clinical trial optimization. This platform has delivered over 100 drug and diagnostic targets, with notable advancements in oncology, metabolic, rare, and CNS diseases. BPGbio's lead drug candidate, BPM31510 IV, is in Phase 2b trials for glioblastoma multiforme and pancreatic cancer, demonstrating significant increases in patient survival. Dr. Narain's leadership at BPGbio has also led to the identification of novel "undruggable" targets, such as Ubiquitin-Conjugating Enzymes (E2s), which have advanced programs in oncology, cardiology, and neurology. His commitment to integrating cutting-edge technology with deep biological insights has positioned BPGbio as a leader in the biopharmaceutical industry. Beyond his critical contributions at BPGbio, Dr. Narain influences global healthcare through strategic initiatives and partnerships with organizations like NASA, the DoD, and Harvard Law School’s Petrie-Flom Center. His extensive publication record and collaborations with academia and industry reflect his dedication to advancing medical science. With over 400 issued and pending patents, Dr. Narain’s contributions underscore his commitment to driving innovation and improving patient care. Dr. Narain's pioneering work continues to shape the future of healthcare, setting new standards in drug discovery and development.